Current Medicinal Chemistry,
Год журнала:
2022,
Номер
30(12), С. 1458 - 1461
Опубликована: Сен. 23, 2022
Abstract:
COVID-19
is
a
contagious
disease.
Paxlovid,
combination
of
Nirmatrelvir
and
Ritonavir,
was
granted
emergency
use
authorization
by
the
United
States
Food
Drug
Administration
(FDA)
for
treatment
on
December
22,
2021.
These
are
peptidomimetic
coronavirus
main
protease
inhibitors.
proline
derivative.
The
present
patent
describes
similar
proline-
like
compounds,
their
preparation,
use,
pharmaceutical
composition,
treatment.
Molecular Aspects of Medicine,
Год журнала:
2024,
Номер
99, С. 101302 - 101302
Опубликована: Авг. 1, 2024
Modern
methods
of
molecular
diagnostics
and
therapy
have
revolutionized
the
field
medicine
in
recent
years
by
providing
more
precise
effective
tools
for
detecting
treating
diseases.
This
progress
includes
a
growing
exploration
body's
secreted
vesicles,
known
as
extracellular
vesicles
(EVs),
both
diagnostic
therapeutic
purposes.
EVs
are
heterogeneous
population
lipid
bilayer
almost
every
cell
type
studied
so
far.
They
detected
body
fluids
conditioned
culture
media
from
living
cells.
play
crucial
role
communication
between
cells
organs,
locally
over
long
distances.
recognized
their
ability
to
transport
endogenous
RNA
proteins
cells,
including
messenger
(mRNA),
microRNA
(miRNA),
misfolded
neurodegenerative
proteins,
several
other
biomolecules.
review
explores
dual
utilization
EVs,
serving
not
only
purposes
but
also
platform
delivering
molecules
tissues.
Through
an
composition,
biogenesis,
selective
cargo
packaging,
we
elucidate
intricate
mechanisms
behind
via
highlighting
potential
use
applications.
Finally,
it
addresses
challenges
outlines
prospective
directions
clinical
EVs.
Infectious Diseases and Therapy,
Год журнала:
2024,
Номер
13(1), С. 155 - 172
Опубликована: Янв. 1, 2024
Limited
data
exist
regarding
real-world
utilization
of
nirmatrelvir/ritonavir.
We
identified
predictors
nirmatrelvir/ritonavir
use
among
Veterans
Affairs
(VA)
outpatients
nationally.
conducted
a
retrospective
cohort
study
with
coronavirus
disease
2019
(COVID-19)
who
were
eligible
to
receive
between
January
and
December
2022,
identify
factors
associated
(i.e.,
demographics,
medical
history,
prior
medication
healthcare
exposures,
frailty,
other
clinical
characteristics)
using
multivariable
logistic
regression.
included
309,755
COVID-19
for
nirmatrelvir/ritonavir,
whom
12.2%
received
Nirmatrelvir/ritonavir
uptake
increased
from
1.1%
23.2%
over
the
period.
Factors
receipt
receiving
booster
vs.
none
(adjusted
odds
ratio
[aOR]
2.19
[95%
confidence
interval
[CI]
2.12–2.26]),
age
≥
50
18–49
years
(aORs
>
1.5
all
groups
years),
having
HIV
(aOR
1.36
[1.22–1.51]),
being
non-frail
severely
frail
1.22
[1.13–1.33]),
rheumatoid
arthritis
1.12
[1.04–1.21).
Those
concomitant
potentially
interacting
antiarrhythmics
0.35
[0.28–0.45]),
anticoagulants/antiplatelets
0.42
[0.40–0.45]),
and/or
psychiatric/sedatives
0.84
[0.81–0.87])
less
likely
Despite
increases
time,
overall
was
low.
Predictors
consistent
known
risk
progression
severe
COVID-19,
including
older
underlying
conditions.
Unvaccinated
undervaccinated
patients
those
medications
cardiovascular
or
mental
health
conditions
(antiarrhythmic,
alpha-1
antagonist,
anticoagulant/antiplatelet,
sedative/hypnotic/psychiatric)
Further
education
prescribers
about
treatment
guidelines
is
needed
improve
in
certain
high-risk
subpopulations.
Vaccines
are
considered
the
most
effective
tools
for
preventing
diseases.
In
this
sense,
with
Covid-19
pandemic,
effects
of
which
continue
all
over
world,
humanity
has
once
again
remembered
importance
vaccine.
Also,
various
epidemic
outbreaks
that
occurred
previously,
development
processes
vaccines
against
these
viral
pathogens
have
accelerated.
By
efforts,
many
different
new
vaccine
platforms
been
approved
commercial
use
and
introduced
to
landscape.
addition,
innovations
made
in
production
carried
out
conventionally
produced
types
create
a
rapid
response
prevent
potential
epidemics
or
pandemics.
situation,
cell
lines
being
positioned
at
center
generation
as
expression
platforms.
Therefore,
since
main
goal
is
produce
fast,
safe,
disease,
addition
existing
systems,
not
used
until
now
included
first
time.
review,
current
clinical
today
described.
Then,
reason
using
lines,
vaccines,
general
culture-based
mentioned.
selection
parameters
animal
explained
by
considering
bioprocess
efficiency
regulations.
Finally,
their
properties
summarized,
an
emphasis
on
future
status
cultures
industrial
production.
Cellular & Molecular Biology Letters,
Год журнала:
2023,
Номер
28(1)
Опубликована: Окт. 12, 2023
Abstract
N
6
-methyladenosine
(m
A)
modification
is
a
dynamic,
reversible
process
and
the
most
prevalent
internal
of
RNA.
This
regulated
by
three
protein
groups:
methyltransferases
(“writers”),
demethylases
(“erasers”),
m
A-binding
proteins
(“readers”).
A
related
enzymes
could
represent
an
optimal
strategy
to
deepen
epigenetic
mechanism.
Numerous
reports
have
suggested
that
aberrant
modifications
lead
expression
important
viral
genes.
Here,
we
review
role
in
replication
virus–host
interactions.
In
particular,
focus
on
DNA
RNA
viruses
associated
with
human
diseases,
such
as
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
immunodeficiency
virus
(HIV)-1,
Epstein–Barr
(EBV),
Kaposi’s
sarcoma-associated
herpesvirus
(KSHV).
These
findings
will
contribute
understanding
mechanisms
interactions
design
future
therapeutic
targets
for
treatment
tumors
infections.
Heliyon,
Год журнала:
2023,
Номер
9(3), С. e14419 - e14419
Опубликована: Март 1, 2023
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
which
causes
disease
2019
(COVID-19),
has
devastated
mankind.
To
date,
no
approved
treatment
is
available
to
completely
combat
this
disease.
Although
many
studies
reported
the
potential
of
silver
nanoparticles'
(AgNPs)
action
mechanism
and
effect
against
SARS-CoV-2,
first
clinical
trial
that
aimed
prove
effect.
This
open-label,
randomized,
parallel-group,
investigator-initiated
study
(IIS)
was
conducted
in
India
from
2021
2022
included
40
patients
diagnosed
with
moderately-severe
severe
COVID-19
pneumonia.
proved
a
significantly
higher
survival
rates
(p
<
0.05)
lower
number
days
until
supplemental
oxygenation
required
0.0001)
for
receiving
intravenous
AgNPs
form
AgSept®
addition
standard
treatment.
highlights
importance
administration
virus-induced
Cellular & Molecular Biology Letters,
Год журнала:
2022,
Номер
27(1)
Опубликована: Июль 30, 2022
Abstract
The
pandemic
outbreak
of
coronavirus
disease
2019
(COVID-19)
has
created
health
challenges
in
all
parts
the
world.
Understanding
entry
mechanism
this
virus
into
host
cells
is
essential
for
effective
treatment
COVID-19
disease.
This
can
bind
to
various
cell
surface
molecules
or
receptors,
such
as
angiotensin-converting
enzyme
2
(ACE2),
gain
entry.
Respiratory
failure
and
pulmonary
edema
are
most
important
causes
mortality
from
infections.
Cytokines,
especially
proinflammatory
cytokines,
main
mediators
these
complications.
For
normal
respiratory
function,
a
healthy
air–blood
barrier
sufficient
blood
flow
lungs
required.
In
review,
we
first
discuss
airway
epithelial
cells,
stem
expression
receptors
epithelium.
Then,
suggested
molecular
mechanisms
endothelial
dysfunction
vessel
damage
COVID-19.
Coagulopathy
be
caused
by
platelet
activation
leading
clots,
which
restrict
lead
failure.
Finally,
present
an
overview
effects
immune
non-immune
cytokines
COVID-19-related
